WASHINGTON (MedPage Today) -- The final report from the HORIZONS-AMI trial revealed an increasing mortality benefit for ST-elevation MI patients treated with bivalirudin (Angiomax) -- compared with those who received unfractioned heparin plus abciximab (ReoPro) or eptifibatide (Integrelin), according to the trial's lead investigator.
Read from Source
|
